Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 RA patients: A matched-analysis of the BSRBR-RA.
Lianne Kearsley-FleetAasiyah RokadMan-Fung TsoiSizheng Steven ZhaoMark LuntKath D Watsonnull nullKimmie L HyrichPublished in: Rheumatology (Oxford, England) (2023)
This is the largest matched comparative effectiveness analysis showing patients switched from etanercept originator to biosimilar appear to do just as well with regards to disease activity and drug persistence compared with those who remained on originator. These data will be reassuring to clinicians and patients regarding non-medical switching.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- disease activity
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- chronic kidney disease
- rheumatoid arthritis patients
- prognostic factors
- systemic lupus erythematosus
- peritoneal dialysis
- juvenile idiopathic arthritis
- machine learning
- emergency department
- palliative care
- electronic health record
- artificial intelligence
- big data